FDA approves nogapendekin alfa inbakicept-pmln for bladder cancer
On April 22, 2024, the FDA approved nogapendekin alfa inbakicept-pmln (Anktiva, Altor BioScience, LLC) for non-muscle invasive bladder cancer.
On April 22, 2024, the FDA approved nogapendekin alfa inbakicept-pmln (Anktiva, Altor BioScience, LLC) for non-muscle invasive bladder cancer.
Robert J. Motzer Memorial Sloan Kettering Cancer Center, New York, NY Robert J. Motzer, Konstantin Penkov, Hirotsugu Uemura, Matthew T Campbell, Christian K. Kollmannsberger, Jae-Lyun…
Robert J. Motzer Memorial Sloan Kettering Cancer Center, New York, NY Robert J. Motzer, Konstantin Penkov, Hirotsugu Uemura, Matthew T Campbell, Christian K. Kollmannsberger, Jae-Lyun…
On Tuesday, December 12, 2023, CDER’s Office of Communication, Division of Drug Information (DDI) will host a webinar titled: FDA Drug Topics: An Overview of…
Explore the program for the AACR Special Conference: Pancreatic Cancer, September 15-18, 2024 in Boston, Massachusetts.
Three-year grants of $350,000 support independent investigators conducting innovative research focused on TTFields.
This Viewpoint discusses dismantling language barriers via multipronged approaches grounded in innovation, human-centered design, and systems thinking in 3 key areas.
The agency is launching a new campaign today called “Prescribe with Confidence” to help raise awareness about OUD and to provide resources for clinicians.
17th AACR Conference on The Science of Cancer Health Disparities in Racial/Ethnic Minorities and the Medically Underserved
Vyaire Medical recalls Twin Tube due to potential nozzle separation risk posing a choking hazard.